Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Nov 8 - Nov 13
Retatrutide (LY3437943) is an investigational triple-agonist (GLP-1, GIP, glucagon) and is not an approved therapy
The most commonly reported adverse effects in the Phase 2 trial included: Nausea the most prevalent side effect, particularly during dose escalation Vomiting Diarrhoea Constipation Decreased appetite (which, whilst contributing to weight loss, can be uncomfortable) Eructation (belching) Injection-site reactions (such as redness, bruising, or discomfort at the injection site) These effects are typically mild to moderate in severity and tend to be most pronounced during the first few weeks of treatment or following each dose increase
Drugmakers have lowered out-of-pocket costs in recent months, but many patients still pay about $350 a month
Great delivery system
The test analyzes genetic variants in GIPR (rs1800437) pathways that influence how your body responds to semaglutide
US$ 21.61
.jpeg)
US$ 21.34
US$ 21.28
US$ 25.84
US$ 28.78
![Metro Marine High-Output Submersible Underwater Light w/Intelligent Monochromatic LEDs - Aqua, 90 Beam [F-BMR1-A3-90] Brand_Toadfish](https://cdn.shopify.com/s/files/1/0499/1942/6726/files/100338XL.jpg?v=1713224032)
